SCHEMBL23218992

SCHEMBL23218992

Cc1cc2c(o1)c(Br)cc1c(CO)c(C)oc12

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29591413 1.00 NQO1 (0.31) NQO1ALDH1A1
SCHEMBL23219033 0.86 ALDH1A1 (0.31) ALDH1A1
SCHEMBL29591308 0.86 ALDH1A1 (0.31) ALDH1A1
SCHEMBL23218103 0.79 SIRT2 (0.42) NQO1
SCHEMBL29591281 0.79 HTR2A (0.35) ALDH1A1
SCHEMBL23219021 0.79 HTR2A (0.35) ALDH1A1
SCHEMBL29591427 0.74
SCHEMBL23219022 0.74
SCHEMBL23218735 0.74 POLB (0.40) ALDH1A1
SCHEMBL29591463 0.74 POLB (0.40) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed